Filter by year
-
november252019
Newron Receives Second Tranche from Financing Agreement with European Investment Bank (EIB)
-
november192019
Newron Receives FDA Rare Pediatric Disease Designation for Sarizotan for the Treatment of Rett Syndrome
-
october292019
Newron Initiates Outreach on First Global Rett Syndrome Burden of Illness Survey in Collaboration with the Rett Community
-
september202019
Newron Pharmaceuticals: Commercialization partner Meiji Seika together with Eisai announce the approval of safinamide for Parkinson’s disease in Japan
-
september122019
Newron reports half-year 2019 results
-
july102019
Newron’s commercialization partner Zambon and Valeo Pharma announce the launch of Onstryv® (safinamide) for Parkinson’s disease in Canada
-
june282019
Newron Receives First Tranche from Financing Agreement with European Investment Bank (EIB)
-
june272019
Newron Pharmaceuticals now also listed on the primary market of the Düsseldorf Stock Exchange and on XETRA
-
june132019
Newron Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
-
may282019
Newron Pharmaceuticals provides update on regulatory status of evenamide for the treatment of schizophrenia
-
may232019
Newron Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference
-
april22019
Shareholders accepted all motions at the 2019 AGM
-
march52019
Newron announces 2018 financial results and provides outlook for 2019
-
february282019
Newron Supports Global Rare Disease Day® 2019
-
february202019
Newron to Present at the 8th Annual SVB Leerink Global Healthcare Conference
-
february12019
Newron Completes Patient Enrollment in Pivotal STARS Study
-
january312019
Newron Pharmaceuticals to Present at the 21st Annual BIO CEO & Investor Conference in New York
-
january162019
Zambon together with Valeo Pharma announce the approval of Onstryv® (safinamide) for PD in Canada